Company: RVRC
Filing Date: 2025-02-14
Form Type: S-1
Source: 0001213900-25-013823
Chunk: 123

Company: Revium Rx.
Filing Date: 2025-02-14
Form: S-1
Chunk 123
---
 |      - |   |
|                                                             |     | 13,578 |   |
| Identifiable assets acquired and liabilities assumed        |     |        |   |
| Short term deposit                                          |     |      7 |   |
| Other receivables                                           |     |    212 |   |
| Fixed assets, net                                           |     |      2 |   |
| Account payable                                             |     |   (182 | ) |
| Other account payables                                      |     |    (87 | ) |
| Intangibles and Goodwill                                    |     | 13,626 |   |
| Total identifiable assets acquired, and liabilities assumed |     | 13,578 |   |

Below proforma information for profit and loss as if the acquisition took place as of January 1, 2024:

|          |     | Successor |       |     | Predecessor |       |     | Adjustments |   |     | Consolidated |       |
|          |     | Unaudited |       |     |             |       |     | Unaudited   |   |     |              |       |
| Net loss |     |           | 4,504 |     |             | 1,792 |     |             | - |     |              | 6,296 |

<div align='center'>F-16</div>

REVIUM RX.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

U.S. dollars in thousands, except share and per share data

NOTE 5 – BASIC AND DILUTED LOSS PER SHARE :

Basic loss per share is computed by dividing the net loss available to common shareholders by the weighted average number of shares outstanding during the reporting period. Diluted loss per share is computed similarly to basic loss per share except that the weighted average number of shares outstanding is increased to include additional shares from the assumed exercise of stock options and warrants, if dilutive. The average number of shares is calculated by assuming that outstanding conversions were exercised and that the proceeds from such exercises were used to acquire common shares at the average market price during the reporting period, potentially dilutive common shares issuable upon the exercise of warrants and options were not included in the computation of loss per share because their effect was anti-dilutive

The loss and the weighted average number of shares used in computing basic and diluted net loss per share for the period commencing January 1 through July 24,2024 through September 30,202